Cadrenal Therapeutics' SEC filings document the regulatory record of a Nasdaq-listed, emerging-growth biopharmaceutical company focused on immune, thrombotic, and anticoagulation-related disorders. Its 8-K reports disclose financial results, Regulation FD updates, clinical and regulatory events for CAD-1005, and scientific research involving 12-lipoxygenase inhibition.
The filings also cover capital-structure activity, including common-stock registrations, at-the-market offering materials, registered direct offerings, private-placement warrants, and related material agreements. Company disclosures identify its Delaware corporate status, Nasdaq Capital Market common stock listing, governance status as an emerging growth company, and formal reporting of pipeline developments involving CAD-1005, tecarfarin, and frunexian.
Cadrenal Therapeutics insider Form 4 summary: Director, CEO and Chairman Quang Pham reported pre-arranged sales of common stock under a Rule 10b5-1 trading plan. On 09/29/2025 he sold 419 shares at a weighted average price of $14.01, and on 10/01/2025 he sold 881 shares at a weighted average price of $14.01. Following these transactions Mr. Pham directly beneficially owned 202,633 shares. He also has indirect beneficial ownership of 200,000 shares through The PVBQ Living Trust, for which he is trustee and retains sole voting and dispositive power.
Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 reporting a proposed sale of 881 common shares through Merrill Lynch (address listed) with an approximate aggregate market value of $12,343.19 and an approximate sale date of 10/01/2025 on NASDAQ. The filing states these shares were acquired as Founders Shares on 01/25/2022 from the issuer and payment was recorded on the acquisition date. The notice also lists prior open-market sales by Quang X. Pham during the past three months totaling 14,819 shares on multiple dates between 08/27/2025 and 09/29/2025 with aggregate gross proceeds reported in the filing. The filer represents no undisclosed material adverse information and includes the standard Rule 144/10b5-1 attestations.
Cadrenal Therapeutics, Inc. (CVKD) notice reports a proposed sale of 1,700 common shares, with an aggregate market value of $23,511, representing part of 2,046,854 shares outstanding. The sale is scheduled approximately for 10/01/2025 and the broker listed is Morgan Stanley Smith Barney LLC.
The shares to be sold were acquired as Founders Shares on 05/17/2022. Over the past three months the filer completed 5 sales totaling 14,500 shares for aggregate gross proceeds of $203,567.01 under 10b5-1 plans on dates between 08/27/2025 and 09/29/2025. The filer certifies no undisclosed material adverse information.
Cadrenal Therapeutics (CVKD) Form 144 notice: An insider proposes a Rule 144 sale of 419 common shares through Merrill Lynch with an aggregate market value of $5,869.50, planned for 09/29/2025. The shares were acquired as founders shares on 01/25/2022. The filing reports 2,046,854 shares outstanding for the issuer. The filer previously sold common stock in the past three months on 08/27/2025, 08/28/2025, 09/24/2025 and 09/25/2025 totaling 14,400 shares for $201,765.14 in gross proceeds. The notice includes the required signature attesting no undisclosed material information.
Cadrenal Therapeutics (CVKD) filed a Form 144 notifying a proposed sale of 100 common shares through Morgan Stanley Smith Barney with an aggregate market value of $1,403, scheduled approximately for 09/29/2025. The filing reports total shares outstanding of 2,046,854, and shows the 100 shares were acquired as founders shares on 05/17/2022. The filer represents compliance with Rule 144 and states no undisclosed material adverse information. The filing also lists recent Rule 10b5-1 sales by Matthew Szot totaling 14,400 shares between 08/27/2025 and 09/25/2025 for gross proceeds of $179,166.01.
Cadrenal Therapeutics, Inc. (CVKD) filing is a Form 144/A notice reporting a proposed sale of 6,790 common shares through Merrill Lynch (Ponte Vedra Beach, FL) with an approximate aggregate market value of $95,661.94, and an approximate sale date of 09/25/2025 on NASDAQ. The shares were acquired as Founders Shares on 01/25/2022. The filing also discloses three insider sales in the past three months by Quang X. Pham totaling 7,610 shares for gross proceeds of $106,104.20 across sales on 08/27/2025, 08/28/2025, and 09/24/2025. The notice includes the required certification that the seller is not aware of undisclosed material adverse information.
Matthew K. Szot, Chief Financial Officer of Cadrenal Therapeutics, Inc. (CVKD), reported sales of company common stock on two dates. On 09/24/2025 he sold 1,500 shares at a weighted average price of $13.9953, and on 09/25/2025 he sold 10,900 shares at a weighted average price of $14.0534, for a total of 12,400 shares sold. After these transactions the reporting person beneficially owned 18,933 shares, down from 29,833 shares following the first sale. The Form 4 is signed by the reporting person on 09/26/2025 and includes explanatory notes that the reported sales occurred in multiple transactions within the stated price ranges.
Cadrenal Therapeutics insider Form 4 summary: Quang Pham, CEO, Chairman, director and reported 10% owner of Cadrenal Therapeutics, Inc. (CVKD), reported sales of company common stock on 09/24/2025 and 09/25/2025. On 09/24/2025 he sold 2,581 shares at $13.99 each, leaving 210,723 shares directly owned after that transaction. On 09/25/2025 he sold 6,790 shares in multiple transactions with a weighted average price of $14.09, leaving 203,933 shares directly owned after those sales. Mr. Pham also has indirect ownership of 200,000 shares held by The PVBQ Living Trust; he is Trustee with sole voting and disposition power and the trust’s sole beneficiary is his child. The filing was signed by an attorney-in-fact on 09/26/2025.
Form 144 filed for Cadrenal Therapeutics, Inc. (CVKD) reporting proposed and recent insider sales. The notice shows a proposed sale of 6,790 common shares through Merrill Lynch (Ponte Vedra Beach, FL) with an aggregate market value of $95,661.94 and an approximate sale date of 09/24/2025 on NASDAQ. The shares were acquired as Founders Shares on 01/25/2022 from the issuer. The filing also discloses sales by Quang X. Pham during the past three months: 3,836 shares on 08/27/2025 (gross proceeds $53,455.56), 1,193 shares on 08/28/2025 (gross proceeds $16,540.64), and 2,581 shares on 09/24/2025 (gross proceeds $36,108), totaling $106,104.20 in gross proceeds.
Form 144 notice for Cadrenal Therapeutics, Inc. (CVKD) reports a proposed sale of 10,900 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $150,202 and an approximate sale date of 09/25/2025 on NASDAQ. The shares were acquired as founders' shares on 05/17/2022 from the issuer and the filer indicates payment was made on that date.
The filing also discloses three recent 10b5-1 sales by Matthew Szot totaling 3,500 shares for gross proceeds of $48,984.95, with trades dated 08/27/2025, 08/28/2025 and 09/24/2025. The filer certifies no undisclosed material adverse information and references a trading plan where applicable.